Maternal Serum Screening in Ontario Using the Triple Marker Test

Going the distance: the influence of practice location on the Ontario Maternal Serum Screening Program.

BACKGROUND The Ontario Maternal Serum Screening (MSS) Program was introduced by the Ontario Ministry of Health as a province-wide pilot project in 1993. The objective of this study was to determine the influence of practice location on Ontario health care providers' use of and opinions regarding MSS, access to follow-up services and recommendations about the program. METHODS A questionnaire w...

Maternal serum screening.

Second trimester maternal dimeric inhibin-A in the multiple-marker screening test for Down's syndrome.

The aim of this study was to evaluate the additional value of dimeric inhibin-A serum concentration in second trimester multiple-marker screening tests for pregnancies affected by Down's syndrome. We anticipated that second trimester maternal serum dimeric inhibin-A concentrations would be altered in pregnancies complicated by fetal Down's syndrome and that dimeric inhibin-A would perform bette...

Ontario Maternal Serum Screening Program: practices, knowledge and opinions of health care providers.

OBJECTIVE To determine the practices, knowledge and opinions of health care providers regarding a prenatal genetic screening program in Ontario. DESIGN Cross-sectional self-reported survey. SETTING Ontario. PARTICIPANTS Random sample of 2000 family physicians, all 565 obstetricians and all 62 registered midwives in the province. Among subjects who were eligible (those providing antenatal ...

Maternal Serum Alpha-Fetoprotein Screening

Background: The maternal serum alpha-fetoprotein test (MSAFP) was developed to screen for neural tube defects. Little is known about the adoption of the MSAFP test. This study examines the effect of provider specialty and geographic location and patient insurance status on MSAFP test use in Washington State. Methods: We conducted a retrospective cohort study of MSAFP use in low-risk obstetric p...